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Background
According to the World Health Organization (WHO), tuberculosis (TB) is the most important cause of
mortality from infectious diseases, with 1.4 million deaths and 10.4 million cases of disease in 2015 [1].
Furthermore, the high global TB burden was compounded by an estimated 480000 new cases of
multidrug-resistant TB (MDR-TB) and 100000 patients with rifampicin-resistant TB (RR-TB) – which are
more difficult to treat – in 2015 [1]. In the WHO European Region, 36970 deaths were reported, in
association with over 320000 TB incident cases [1, 2].
Worldwide, the annual decline in the TB incidence rate from 2014 to 2015 was only 1.5%. However, to
achieve the first milestones of the End TB Strategy, this indicator should increase to 5% by 2020 and then
accelerate further [2].
Although TB disproportionately affects vulnerable population groups (i.e. individuals at higher risk of
exposure to discrimination, hostility or economic adversity, such as migrants and refugees, or
immune-suppressed individuals either from HIV infection or biological therapy), Mycobacterium
tuberculosis transmission does not respect any borders and can affect virtually anybody living in high-,
middle- or low-income countries. Occurrence of the disease generates unacceptable human suffering and
catastrophic costs to patients and their families, as well as to society as a whole [3–6].
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Sustainable and effective efforts are thus needed to ensure quality prevention, diagnosis and treatment for
TB and latent TB infection (LTBI) [5, 6]. These should be implemented immediately as integral parts of
both the human rights of affected individuals and public health prerequisites to control and eliminate TB,
while preventing further development of MDR-TB and extensively drug-resistant TB (XDR-TB) [7, 8].
On the occasion of World TB Day 2017 and as a strong message contributing to the Ministerial Conference
“A multisectoral response to end TB in the sustainable development era”, to be held in Moscow on
November 16–17, 2017, the European Respiratory Society (ERS) and the UNION (International Union
against Tuberculosis and Lung Disease) Europe Region would like to highlight the following statements:
1) TB is neither highly virulent nor easily transmitted, and is treatable. Therefore, efforts should be
implemented to rapidly detect and treat it (both drug-susceptible and M/XDR-TB cases). Provision of
adequate treatment is, in fact, essential to break the chain of transmission within the community, while
protecting uninfected individuals by the extent possible [5, 6, 8].
2) Diagnosis of LTBI, TB and M/XDR-TB is not always easy to perform in all settings and circumstances,
particularly in centres hosting large numbers of at high-risk individuals including migrants and refugees
[4, 9–15]; therefore, national political commitment is immediately required to address this important gap
in the cascade of care.
3) Sub-optimal or inappropriate medical management of LTBI, TB and M/XDR-TB and/or inadequate
follow-up of individuals or patients will hinder TB control and elimination efforts [5, 6, 9]; therefore,
education of healthcare workers and identification of reference centres should be a priority to improve the
public health outcomes and reduce the waste of healthcare-related financial resources.
Recommendations
Health authorities, national TB programmes, national and international technical agencies, civil society
organisations and donor agencies are urged to prioritise TB prevention, care and control, particularly
among the most vulnerable populations, with the following strong recommendations.
TB prevention
• Implement the necessary infection control measures (managerial activities, administrative and
environmental controls, personal protection) [9–11].
• Implement the principles of the WHO LTBI guidelines in terms of both diagnosis and treatment [6].
• Implement the LTBI monitoring and evaluation activities recently proposed by WHO [6, 16].
• Advocate for more effective medicines for LTBI management, including the registration of rifapentine
in Europe to allow the prescription of shorter and effective regimens to treat LTBI [6].
• Promote research on new, effective vaccines and diagnostics and shorter and more effective treatment
regimens [1].
TB diagnosis
• Scale up rapid diagnosis of TB and drug resistance forms using the diagnostic WHO endorsed
molecular methods and referral of the patient to treatment services [1, 5, 9, 17].
TB treatment
• Ensure people-centred, age-sensitive, gender-specific services supporting adherence and universal
access to TB services [1, 5, 9, 17].
• Ensure adequate treatment of drug-susceptible cases, to achieve the highest success rate.
• Implement quality-based management of drug-resistant and MDR-TB cases.
• Promote the use of therapeutic drug monitoring to prevent, detect and manage adverse events [18, 19].
• Promote continuous medical education on TB for all healthcare workers potentially in charge of TB cases.
• Consider psychosocial support and relevant measures to enable and support the patients and their
families to complete their treatment.
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